Company intelligence / Profile preview
Annexon Biosciences
Brisbane, California, United Statesannexonbio.com ↗
- Ownership
- Public · ANNX
- Employees
- ~51
- Development stage
- Other
01
Overview
ANX005 completed enrollment in its first Phase 3 pivotal program for Guillain-Barré Syndrome in 40 years[1]. ANX007 demonstrated statistically significant, dose-dependent preservation of visual function in Phase 2 trial for geographic atrophy, with Phase 3 data expected in 2H26[1]. ANX1502 achieved target pharmacokinetics in Phase 1 healthy volunteer study[1].
- Therapeutic areas
- OphthalmologyHematologyImmunologyNeurology
- Modalities
- Monoclonal antibodyMonoclonal antibody fragmentSmall molecule
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Financials
- Market cap
- $656.2M
- Total revenue
- $0
- Enterprise value
- $471.6M
Beyond the preview
Go deeper on Annexon Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Annexon Biosciences.